| 1 |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
|
| 2 |
Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlapsyndromes[J]. Hematology Am Soc Hematol Educ Program, 2020, 2020(1): 450-459.
|
| 3 |
韦美萍, 张敬宇, 高占玺, 等. MDS/MPN伴环形铁粒幼细胞和血小板增多2例并文献复习[J]. 临床检验杂志, 2018, 36(6): 476-478.
|
| 4 |
Gurevich I, Luthra R, Konoplev SN, et al. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings[J]. Am J Clin Pathol, 2011, 135(3): 398-403.
|
| 5 |
朱雨, 何广胜. 世界卫生组织2016年骨髓增殖性肿瘤及骨髓增生异常综合征/骨髓增殖性肿瘤分类更新解读[J]. 中国实用内科杂志, 2016, 36(8): 658-661, 667.
|
| 6 |
Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations[J]. Haematologica, 2015, 100(4): e125-e127.
|
| 7 |
何广胜. 骨髓增生异常/骨髓增殖性肿瘤伴环状铁粒幼细胞和血小板增多的诊断与治疗[J]. 临床血液学杂志, 34, 11(2021): 762-764.
|
| 8 |
Jeromin S, Haferlach T, Weissmann S, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations[J]. Haematologica, 2015, 100(4): e125-e127.
|
| 9 |
Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management"[J]. Am J Hematol, 2019, 94(4): 475-488.
|
| 10 |
曹蓝, 洪鸣. 骨髓增生异常综合征/骨髓增殖性肿瘤的治疗进展[J]. 临床血液学杂志, 2021, 34(9): 680-683.
|
| 11 |
肖志坚. 骨髓增生异常综合征/骨髓增殖性肿瘤的诊断和治疗[J]. 中国实用内科杂志, 2018, 38(2): 93-97.
|
| 12 |
Antelo G, Mangaonkar AA, Coltro G, et al. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)[J]. Br J Haematol, 2020, 189(3): e104-e108.
|
| 13 |
Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes[J]. N Engl J Med, 2020, 382(2): 140-151.
|
| 14 |
Chan O, Komrokji RS. Luspatercept in the treatment of lower-risk myelodysplastic syndromes[J]. Future Oncol, 2021, 17(12): 1473-1481.
|
| 15 |
周炯涛, 何广胜. SF3B1突变型骨髓增生异常综合征亚型发病机制及诊断[J]. 中国实用内科杂志, 2021, 41(1): 27-29.
|
| 16 |
Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms[J]. Am J Hematol, 2018, 93(2): 277-285.
|
| 17 |
Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia[J]. Blood, 2010, 116(8): 1205-1210; quiz 1387.
|
| 18 |
Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis[J]. Haematologica, 2012, 97(7): 1036-1041.
|
| 19 |
Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera[J]. Semin Thromb Hemost, 2006, 32(6): 589-604.
|
| 20 |
Nichele I, Ruggeri M, Rodeghiero F. Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation[J]. Am J Hematol, 2015, 90(8): E148-E149.
|
| 21 |
Nicolosi M, Mudireddy M, Vallapureddy R, et al. Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)[J]. Am J Hematol, 2018, 93(1): e27-e30.
|
| 22 |
Hunter AM, Al Ali N, Sallman DA, et al. WHO defined Chronic Myelomonocytic Leukemia-2(CMML- 2)patients rapidly progres to AML suggesting this entity represents a transitory clinical state [C]. Blood, 2019, 134(Supplement_1): 1717.
|
| 23 |
Kim J, Kim YR, Lee KA. Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine[J]. Leuk Lymphoma, 2012, 53(11): 2287-2289.
|
| 24 |
Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study[J]. Semin Hematol, 2018, 55(4): 248-255.
|
| 25 |
Azizi A, Ediriwickrema A, Dut ta R, et al. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes:a retrospective evaluation of a real-world experience[J]. Leuk Lymphoma, 2020, 61(11): 2700-2707.
|
| 26 |
李叶琼, 包慎, 冶秀鹏, 等. 伴SF3B1基因突变的MDS/MPN-RS-T 1例临床分析并文献复习[J]. 现代肿瘤医学, 2020, 28(3): 481-483.
|
| 27 |
尹晶晶, 唐倩, 谷佳礼, 等. 探究新型端粒酶抑制剂Nilo 22对白血病细胞的杀伤作用与机制[J]. 中国实验血液学杂志, 2021, 29(4): 1056-1064.
|
| 28 |
Elghouat G, Yahyaoui H, Raissi A, et al. MDS/MPN-RS-T: a case report[J]. Ann Biol Clin (Paris), 2021, 79(4): 369-370.
|
| 29 |
Montalban-Bravo G, Garcia-Manero G. MDS/MPN-RS-T justified inclusion as a unique disease entity?[J]. Best Pract Res Clin Haematol, 2020, 33(2): 101147.
|
| 30 |
王术国, 周霞, 马树沛. 骨髓增生异常/骨髓增殖性肿瘤伴环形铁粒幼细胞和血小板增多一例报告并文献复习[J]. 中华肿瘤防治杂志, 2020, 27(23): 1937-1939.
|
| 31 |
宫文玉, 徐士云, 金其川, 等. 伴环形铁粒幼细胞和血小板增多的骨髓增生异常综合征/骨髓增殖性肿瘤2例并文献复习[J]. 白血病·淋巴瘤, 2022, 31(2): 103-106.
|